Natural History of Hypoparathyroidism in adults

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient secretion or action of parathyroid hormone (PTH), leading to chronic hypocalcaemia and disturbances in phosphate and vitamin D metabolism. The condition may arise from a variety of etiologies, including postsurgical damage or removal of the parathyroid glands, autoimmune destruction, genetic defects affecting parathyroid development or function, and infiltrative diseases. Despite advances in diagnosis and management, hypoparathyroidism remains associated with significant morbidity, including neuromuscular symptoms, neurocognitive impairment, renal complications, and reduced quality of life. Current treatment strategies – primarily based on calcium supplementation and active vitamin D analogues – address biochemical abnormalities but do not fully replicate the physiological actions of PTH, underscoring the need for a deeper understanding of the disease course. 

The natural history of hypoparathyroidism is incompletely characterized, particularly across diverse patient populations and etiological subtypes. Most available data are derived from small, single-center studies or retrospective cohorts, which limit the generalizability of findings and the ability to identify long-term trends and predictors of outcomes. Furthermore, variations in clinical practice, monitoring strategies, and therapeutic approaches across regions contribute to heterogeneity in patient outcomes. As a result, there remain critical gaps in knowledge regarding disease progression, complication rates, treatment effectiveness, and factors influencing prognosis. 

The EuRREB Registry provides a unique and valuable platform to address these gaps. As a multinational, multicenter registry encompassing a broad spectrum of rare bone and mineral disorders, it facilitates the systematic collection of standardized clinical, biochemical, genetic, and patient-reported data. Its wide geographic coverage and inclusion of both well-resourced and underrepresented regions enhance the representativeness of the data and enable comparative analyses across healthcare systems and patient groups.   

Objective

The main objective is to investigate the natural history of hypoparathyroidism in a large, real-world cohort. By analyzing longitudinal data, the study aims to characterize patterns of disease onset, progression, and complications, as well as to evaluate the impact of different treatment strategies on clinical and biochemical outcomes. Particular attention will be given to identifying risk factors for adverse events such as nephrocalcinosis, chronic kidney disease, and impaired quality of life. Additionally, the study will explore differences in disease trajectory across etiological subtypes, age groups, and geographic regions. 

The Methodology 

The aim is to collect the clinical characteristics of 1000 hypopara patients within 3 years time. Then the analysis of the Core registry common data elements and data from the Hypoparathyroidism module, including PROMs results, for patients >18 years or older at first data entry, will be conducted. 

For publications from this and other study groups, see our publication page.

Members of this Study Group

Initiating Team 

Participating members

For more information regarding the study or if you are interested to contribute to this study, please contact registries@lumc.nl.

*The Principal Investigator (PI) is the lead applicant responsible for submitting the data request and initiating the study.